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INTRODUCTION
Spinal cord injury (SCI) is a devastating neurological disorder 
that leads to motor, sensory, or autonomic dysfunction, and is as-
sociated with high rates of mortality and complications including 
bladder infection, renal failure, cardiovascular disease, and respira-
tory dysfunctions. There are approximately 180,000 new cases of 
SCI worldwide per year caused by traffic accidents, sports injuries, 
and other traumatic events according to an epidemiologic study 
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Spinal cord injury (SCI) causes axonal damage and demyelination, neural cell death, and comprehensive tissue loss, resulting in devastating neuro-
logical dysfunction. Neural stem/progenitor cell (NSPCs) transplantation provides therapeutic benefits for neural repair in SCI, and glial cell line-
derived neurotrophic factor (GDNF) has been uncovered to have capability of stimulating axonal regeneration and remyelination after SCI. In this 
study, to evaluate whether GDNF would augment therapeutic effects of NSPCs for SCI, GDNF-encoding or mock adenoviral vector-transduced 
human NSPCs (GDNF-or Mock-hNSPCs) were transplanted into the injured thoracic spinal cords of rats at 7 days after SCI. Grafted GDNF-
hNSPCs showed robust engraftment, long-term survival, an extensive distribution, and increased differentiation into neurons and oligodendroglial 
cells. Compared with Mock-hNSPC- and vehicle-injected groups, transplantation of GDNF-hNSPCs significantly reduced lesion volume and glial 
scar formation, promoted neurite outgrowth, axonal regeneration and myelination, increased Schwann cell migration that contributed to the my-
elin repair, and improved locomotor recovery. In addition, tract tracing demonstrated that transplantation of GDNF-hNSPCs reduced significantly 
axonal dieback of the dorsal corticospinal tract (dCST), and increased the levels of dCST collaterals, propriospinal neurons (PSNs), and contacts 
between dCST collaterals and PSNs in the cervical enlargement over that of the controls. Finally grafted GDNF-hNSPCs substantially reversed the 
increased expression of voltage-gated sodium channels and neuropeptide Y, and elevated expression of GABA in the injured spinal cord, which are 
involved in the attenuation of neuropathic pain after SCI. These findings suggest that implantation of GDNF-hNSPCs enhances therapeutic effi-
ciency of hNSPCs-based cell therapy for SCI.
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[1]. Traumatic SCI causes extensive spinal tissue damage, loss of 
neural cells, axonal injury, demyelination, and glial scar formation, 
which adversely impact overall patient outcomes and place finan-
cial burdens on healthcare systems. However, there is no standard 
and efficient management approach for SCI patients [2, 3]. 
Neural stem/progenitor cells (NSPCs) transplanted into the 
damaged spinal cord robustly engraft, migrate toward the lesion 
site, differentiate into all three types of neural lineage cells, inte-
grate into host tissues, provide trophic/anti-inflammatory factors, 
regenerate lost neural circuits, and remyelinate injured axons, all 
of which are functionally beneficial following SCI [4-12]. In addi-
tion, human fetal brain or spinal cord-derived NSPCs (hNSPCs) 
implanted into animal models of SCI incorporate into the host 
neural circuitry and improve locomotor function [13-17]. Recent 
clinical trials demonstrate that transplantation of hNSPCs is safe 
and potentially efficacious for treatment of SCI [18-20]. However, 
implanted NSPCs exhibit poor survival, integration, differentia-
tion, and functional neural connections in the inhospitable envi-
ronment of the injured central nervous system (CNS) [4, 5, 21, 22]. 
Thus, the therapeutic efficiency of NSPCs for SCI is insufficient.
Glial cell line-derived neurotrophic factor (GDNF) has develop-
mental, neuroprotective and neurotrophic effects on some types 
of neurons in the CNS and peripheral nervous system [23, 24]. 
Administration of GDNF reduces motor neuron death, second-
ary damage, and white matter atrophy in the spinal cord, increases 
neuronal survival and the number of spared neuronal fibers, 
promotes the survival and proliferation of Schwann cells (SCs), 
and improves motor function post-SCI [25-29]. The methods by 
which GDNF is delivered to the injured spinal cord vary widely, 
and include osmotic minipumps, direct injection, GDNF-releasing 
guidance channels, guidance channels containing SCs and GDNF, 
injectable GDNF-embedded hydrogels, GDNF-releasing biode-
gradable polymeric microspheres, hydrogel scaffolds containing 
GDNF and SCs, and genetically modified GDNF-secreting cells 
[29, 30]. Recent studies suggest that combinational treatments 
using many types of genetically modified cells, including SCs, ol-
factory ensheathing cells, immortalized mouse neural stem cells, 
fibroblasts, bone marrow-derived mesenchymal stem cells (MSCs), 
and umbilical cord blood mononuclear cells or MSCs, have vary-
ing therapeutic potentials for SCI [29, 30]. 
We previously reported that human fetal brain-derived primary 
NSPCs implanted into the injured rat spinal cord robustly engraft, 
migrate, integrate with host cells, and differentiate into neuronal 
and glial cells, although most remain immature cells, resulting in 
improved locomotor recovery. However, a clinical trial in which 
hNSPC were transplanted into patients with traumatic cervical 
SCI reported limited neurological benefit [18]. This study inves-
tigated the regenerative capabilities of hNSPCs transduced with a 
GDNF-encoding or mock adenoviral vector (GDNF- and Mock-
hNSPCs, respectively) implanted into the injured spinal cord of 
adult rats and compared their therapeutic efficiencies for future 
clinical trials involving SCI patients. 
MATERIALS AND METHODS
Culture of hNSPCs 
Human fetal brain tissue was obtained from a cadaver at 13 
weeks of gestation with full parental consent and the approval 
of the Research Ethics Committee of Yonsei University College 
of Medicine, Seoul, Korea (Permit No. 4-2003-0078) [18, 31]. All 
procedures conformed with the guidelines of the National In-
stitutes of Health and the Korean Government. Briefly, hNSPCs 
isolated from the fetal telencephalon were grown as neurospheres 
in serum-free DMEM/F12 (Gibco, Grand Island, NY) containing 
1% (v/v) penicillin/streptomycin (P/S; Gibco), 1% N-2 Supple-
ment (Gibco), 8 μg/mL heparin (Sigma, St. Louis, MO), 20 ng/mL 
fibroblast growth factor-2 (R&D Systems, Minneapolis, MN), and 
10 ng/mL leukemia inhibitory factor (Sigma). All cultures were 
maintained in a humidified incubator containing 5% CO2 and air 
at 37℃. Half of the growth medium was replenished every 3~4 
days.
Construction and transduction of adenoviral vectors
Human GDNF cDNA was cloned by PCR and inserted into the 
CAG-pShuttle plasmid. Adenoviral particles were generated using 
the AdEasy Adenoviral Vector System (Stratagene, La Jolla, CA) 
[31]. hNSPCs were transduced with a GDNF-encoding adenoviral 
vector or a null-encoding adenoviral vector at a multiplicity of 
infection of 40. After 3 days, dissociated single cells were washed 
twice with Hank’s Balanced Salt Solution (Gibco) containing 10 
mM HEPES (Gibco; H-H buffer; pH 7.4) and suspended in H-H 
buffer at a density of 8×104 cells/μL for transplantation.
ELISA
Mock-hNSPCs and GDNF-hNSPCs were seeded into a 24-well 
plate at a density of 2.5×105 cells/well. After 24 or 72 h, media were 
collected and cleared by centrifugation at 3000 rpm for 3 min. The 
levels of human GDNF were measured using a human GDNF 
DuoSet ELISA Development kit (R&D systems) according to the 
manufacturer’s instructions.
In vitro neurite outgrowth assay
SH-SY5Y human neuroblastoma cells were plated into a poly-
L-lysine-coated 6-well plate containing growth medium (MEM/
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F12 containing 10% fetal bovine serum and 1% P/S) at a density 
of 1×105 cells/well and cultured for 24 h. Cells were washed twice 
and then incubated with conditioned medium (CM) of Mock-
hNSPCs (Mock-CM) or GDNF-hNSPCs (GDNF-CM) for 24 h. 
To quantify neurite length, cells were observed under an Olympus 
IX71 microscope and analyzed with NeuronJ Software. For im-
munodepletion, GDNF-CM was pre-incubated with 5 μg/mL 
anti-GDNF (R&D Systems) or isotype-matched IgG antibody 
(R&D Systems) for 30 min at 37℃. After 24 h, neurite lengths were 
measured as described previously [31]. Each data point represents 
the average of the data of three independent replicates. 
Spinal cord injury 
All animal experiments were performed under a protocol ap-
proved by the Institutional Animal Care and Use Committee of 
Yonsei University College of Medicine and in accordance with the 
Guidelines for the Care and Use of Laboratory Animals issued by 
the National Institutes of Health. To avoid controversial effects 
of hormone and gender differences on functional and histologi-
cal outcomes, adult male rats were only used. Adult male Sprague 
Dawley rats (290~310 g) were housed in groups of 4~5 under a 12 
h light-dark cycle. Food and water was provided ad libitum. Trau-
matic contusive SCI was induced as described previously [32, 33]. 
Briefly, rats were anesthetized by intraperitoneally injecting a mix-
ture of 97.5 mg/kg ketamine (Yuhan Co., Seoul, Korea), 4.24 mg/
kg xylazine (Bayern Korea, Seoul, Korea), and 1 mg/kg aceproma-
zine (Samu Median, Seoul, Korea). Laminectomy was performed 
at T9 under sterile conditions. The spinal cord was then contused 
with a NYU weight-drop device. The dorsal surface of the spinal 
cord was compressed by dropping a 10 g rod (diameter: 2.5 mm) 
from a height of 50 mm. The surgical site was sutured in layers. To 
prevent infection, rats were intraperitoneally injected with 50 mg/
kg cefazolin (Chong Kun Dang Pharmaceutical Co., Seoul, Korea). 
The bladder was emptied twice daily. 
Cells transplantation
Animals were randomly assigned to three groups and injected 
with 12 μL GDNF-hNSPCs (8.0×104 cells/μL; n =32), Mock-
hNSPCs (8.0×104 cells/μL; n =26), or H-H buffer (vehicle, n =31) 
at 7 days after SCI. Rats were anesthetized as above and the lami-
nectomy site was re-exposed. Six microliters of cell suspension or 
buffer was injected 1.5 mm rostral and caudal to the lesion center, 
respectively, using a glass micropipette (diameter: 0.3 mm). The 
needle was set at the lesion center along the midline, moved 1.5 
mm rostrally and caudally along the midline, and then inserted 1.0 
mm deep into the spinal cord relative to the dorsal surface. Each 
injection was performed over 1 min. To prevent leakage of cells 
through the injection track, the needle was left in position for 1 
min after completion of the injection. Animals in all groups were 
intraperitoneally injected with 10 mg/kg/d cyclosporine beginning 
1 day before injection and lasting until they were sacrificed. 
Histological assessment and stereological quantification
Adenovirus-infected cells were plated into 8-well chamber slides 
(Nunc, Roskilde, Denmark) coated with 10 mg/mL poly-L-lysine 
(PLL; Sigma) at a density of 8×104 cells/well, and differentiated for 
7 days in DMEM/F12 containing 1% P/S and 1% N-2 Supplement. 
Immunocytochemical analysis of cultured cells was performed 
as described previously [18, 31, 34]. For immunohistochemical 
analysis, animals were deeply anesthetized and perfused transcar-
dially with PIPES buffer (pH 7.4; Sigma) containing 4% parafor-
maldehyde at 9 weeks post-transplantation. The spinal cord was 
subsequently post-fixed in the perfusing solution overnight at 
4℃. Tissues were then cryoprotected in phosphate-buffered saline 
(PBS) containing 30% sucrose for 24~48 h at 4℃. The T8~T10 seg-
ment of the spinal cord was separated and embedded in O.C.T 
compound medium (Sakura Finetek, Torrance, CA). Coronal or 
sagittal cryostat sections of the cord (16 μm thick) were stained 
with the antibodies listed in Table 1, as described previously [18, 
31]. For the evaluation of the differentiation patterns of engrafted 
GDNF- and Mock-hNSPCs in the injured spinal cord, one series 
of parasagittal sections of the spinal cord of rats injected with 
Mock- or GDNF-hNSPCs (n=6 per group), each separated by 80 
μm, were analyzed with immunohistochemistry. The number of 
total human cell-specific marker+ cells and colocalized cells with 
human cell- and neural cell type-specific markers were counted in 
the four representative regions (injury epicenter, spared tissue ad-
jacent to the epicenter, and sequential 1 mm segments rostral and 
caudal to the injury epicenter) in each individual series. The num-
ber of engrafted cells differentiated into specific neutral cell types 
is expressed as a percentage of the total number of donor-derived 
cells in both groups.
The images were acquired using a confocal microscope (LSM700; 
Carl Zeiss, Oberkochen, Germany) and a BX51 microscope 
(Olympus, Center Vally, PA). Stereology was conducted using a 
BX51 microscope and ImageJ software (National Institutes of 
Health) [35]. Systematic random sampling of the tissue was per-
formed according to stereological principles. Starting sections were 
chosen at random and every sixth section thereafter was analyzed 
[14]. 
Lesion volume, spared tissue volume, and glial scar area were 
quantified in parasagittal sections of the spinal cord of rats injected 
with vehicle, Mock-hNSPCs, or GDNF-hNSPCs (n=5 per group) 
by immunostaining for glial fibrillary acidic protein (GFAP) [14] 
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and using the Cavalieri probe at 4 ×. Lesion volume was quantified 
as the area of the lesion epicenter that was devoid of GFAP stain-
ing using a 90 μm grid. Spared tissue volume was quantified in 4 
mm segments rostral and caudal to the injury epicenter, excluding 
the lesions using a 90 μm grid. Glial scar area was quantified by 
measuring the area of dense GFAP immunostaining near the in-
jury epicenter, excluding the lesion, which was defined as the area 
lacking GFAP immunostaining, using a 90 μm grid [14, 36]. 
Three parasagittal sections (n =5 per group) were collected for 
immunohistochemistry of GABA and the SC marker Schwann/2E 
and stereological analysis. The lesion epicenter was captured us-
ing a BX51 microscope and the immunostaining densities were 
measured using ImageJ. To correct for non-specific labeling, the 
background intensity in a non-immunoreactive area was subtract-
ed from each value. The immunostaining densities of GABA and 
Schwann/2E were normalized against that in the sham-operated 
control.
Ten coronal sections (n =5 per group) of the T8 segment were 
randomly selected and incubated with an anti-NPY antibody fol-
lowed by a biotinylated antibody (Jackson ImmunoResearch, West 
Grove, PA). Signals were visualized using a Vectastatin Elite ABC 
kit (Vector Laboratories, Burlingame, CA) according to the manu-
facturer’s instructions. Images were acquired using a BX51 micro-
scope. The optical density of immunostaining was quantified at 
lamina I of the dorsal horn and normalized against that at lamina 
VII [37]. The optical density of NPY immunostaining density was 
normalized against that in the sham-operated control.
Parasagittal sections (n =5 per group) were stained with Luxol 
Fast Blue (LFB; Sigma) and Cresyl violet (CV; Sigma). Images were 
acquired using a BX51 microscope. The demyelinated area was 
measured as the area of CV staining that was devoid of LFB stain-
ing. The demyelinated volume was calculated using three sections 
spaced 90 μm using Cavalieri’s principle and expressed as a per-
centage of the total cord tissue volume on each slide [38]. 
Ultrastructural imaging
Rats were anesthetized as described above and perfused trans-
cardially with cold PBS followed by 2% PIPES buffer containing 
2% paraformaldehyde and 2% glutaraldehyde (Merck, Darmstadt, 
Germany) at 9 weeks post-transplantation. The T8~T10 segment 
of the spinal cord was separated and post-fixed in the same fixa-
tives overnight at 4℃. Fixed cord tissues were embedded in 3% 
agarose (Sigma) and axially sectioned into 150 μm-thick slices 
using a vibratome (Campden Instruments, Loughborough, Eng-
land). Sections were washed with PBS for 15 min and treated with 
phosphate buffer containing 1% osmium tetroxide for 2 h. After 
Table 1. Lists of antibodies used for immunostaining and primers used for qPCR
Method Antibody Species Dilution Company Cat. no.
Immunocytochemistry/ 
immunohistochemistry
Human nestin Rabbit 1/200 Millipore ABD69
GFAP Rabbit 1/1500 DAKO Z0334
Tuj1 Mouse 1/200 Covance MMS-435-P
O4 Mouse 1/200 Millipore MAB345
PDGFR Rabbit 1/100 Santa Cruz SC-338
GDNF Rabbit 1/50 Santa Cruz SC-328
Immunohistochemistry Ku80 Rabbit 1/200 Cell Signaling 2180
STEM121 Mouse 1/500 Clontech Y40410
STEM101 Mouse 1/100 Clontech Y40400
Human nuclei Mouse 1/50 Chemicon MAB1281
Olig2 Rabbit 1/200 Millipore Ab9610
S100B Goat 1/50 R&D Systems AF1820
Neurofilament L Rabbit 1/1500 Chemicon AB9568
Neurofilament M Rabbit 1/1500 Chemicon AB1987
Neurofilament H Rabbit 1/1500 Chemicon AB1991
MBP Rabbit 1/400 DAKO A0623
Schwann/2E Mouse 1/3000 Cosmo Bio CAG-Gu01-M01AS-A 
GABA Rabbit 1/500 Sigma 2052
Gene (protein) Amplicon length (bp) Primer sequence
SCN3A (Nav1.3) 158 F : 5'-AACGAAAGACGATCAAGACC-3'
R : 5'-CCAAAGAAACATCAACGATCAG-3'
SCN9A (Nav1.7) 163 F : 5'-GGGAACTTGATCTTTACAGGG-3'
R : 5'-ACTGATAATCCTTCCACATCTG-3'
18S rRNA 77 F : 5'-TTGATTAAGTCCCTGCCCTTT-3'
R : 5'-CGATCCGAGGGCCTCACTA-3'
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washing in phosphate buffer, sections were dehydrated in graded 
ethanol solutions, incubated in propylene oxide (Polysciences, 
Warrington, PA) for 10 min, and embedded in Epon mixture 
(Epon® 812; Polysciences). Embedded tissue were sectioned into 
80 nm-thick slices using a ultramicrotome (Leica Microsystems, 
Wetzlar, Germany). The slices were placed on a copper grid (Elec-
tron Microscopy Sciences, Hatfield, PA), and stained in uranyl 
acetate (Polysciences) and lead citrate. Images were acquired using 
a transmission electron microscope (JEM-1011; JEOL, Peabody, 
MA). The myelin G-ratio was quantified as the ratio of the axon 
diameter to the diameter of the axon plus the surrounding myelin 
sheath. The total number of axons sampled in the vehicle-, Mock-
hNSPC-, and GDNF-hNSPC-injected groups (n=5 per group) was 
192, 172, and 164, respectively [39]. 
Tract tracing studies 
Six weeks after administration of GDNF-hNSPCs, Mock-
hNSPCs, or vehicle (n =8 per group), corticospinal tract (CST) 
projections were bilaterally traced under anesthesia with biotinyl-
ated dextran amine (BDA; 10,000 MW, 10% in ddH2O; Invitrogen, 
Grand Island, NY). A glass micropipette needle attached to a 10 
µL Hamilton syringe placed on an infusion pump (KD Scientific, 
Holliston, MA) was stereotactically guided, and 1.0 µL BDA was 
bilaterally injected into four sites over the sensorimotor cortex at a 
depth of 1.5 mm (Bregma -1 mm, sagittal suture 1.5 mm; Bregma 
1 mm, sagittal suture 1.5 mm, respectively). All injections were 
performed over 1 min, and the injection micropipette was kept 
in place for an additional 1 min after completion of the injection 
to minimize leakage upon withdrawal. Animals were sacrificed 
3 weeks later. BDA-labelled fibers were visualized in axial spinal 
cord sections (30 μm) with streptavidin-conjugated Texas Red 
or 3,3’-diaminobenzidine (DAB; Sigma) and ammonium nickel 
sulfate using a Vectastatin Elite ABC Kit (Vector Laboratories, Bur-
lingame, CA) according to the manufacturer’s instructions. The 
number of BDA+ fibers in the dorsal CST (dCST) was determined 
from images acquired with a confocal microscope using ImageJ 
software. Axonal fibers in the dCST were evaluated in three axial 
sections every 1.0 mm from 6.0 mm rostral to 6.0 mm caudal to 
the lesion epicenter. The number of axonal fibers was normalized 
against the number of main dCST fibers in the C1 segment of the 
spinal cord (% fibers). 
In the same groups of rats, the retrograde tracer Fluorogold (FG; 
1.0 µL of 4% FG dissolved in ddH2O; Abcam, Cambridge, MA) 
was stereotactically injected under anesthesia with a glass micropi-
pette into the left and right sides of the spinal cord at the L2 level at 
8 weeks after administration of GDNF-hNSPCs, Mock-hNSPCs, 
or vehicle. Rats were sacrificed 1 week later. The spinal cords were 
removed and divided into five segments (cervical, upper thoracic, 
injury epicenter, lower thoracic, and lumbar parts), and then post-
fixed, cryoprotected, and frozen in O.C.T compound as described 
above. FG-labeled propriospinal neurons (PSNs) were stained 
with an anti-FG antibody and DAB. Sections were mounted with 
Vectashield mounting medium or Permount (Fisher Scientific, 
Fair Lawn, NJ) [40]. To analyze the formation of contacts between 
the cervical dCST and PSNs, BDA-labelled CST collateral fibers 
were visualized in axial spinal cord sections with DAB and am-
monium nickel sulfate, and FG-labeled PSNs were stained with an 
anti-FG antibody and biotinylated secondary antibody, combined 
with streptavidin-HRP in the ABC (Avidin Biotin Complex) 
method. The numbers of collaterals sprouting from the main 
dCST, propriospinal neurons (PSNs), and contacts between dCST 
collaterals and PSNs were counted in 20 consecutive axial sections 
of the cervical enlargement of the spinal cord (C3 to C5) at an in-
terval of 150 μm. To control for variation in the tracing efficiency, 
the number of collaterals from the dCST was divided by the num-
ber of main dCSTs in the same sections. The number of contacts 
between dCST collaterals and PSNs was also counted in the same 
sections.
Quantitative real-time reverse transcription-polymerase 
chain reaction (qRT-PCR)
At 9 weeks post-transplantation, total RNA was isolated from the 
T8~T10 segment of the spinal cord in rats injected with GDNF-hN-
SPCs, Mock-hNSPCs, and vehicle as well as sham-operated con-
trols (n=5 per group) using TRI reagent (Molecular Research Cen-
ter, Cincinnati, OH). Thereafter, 4 µg RNA was reverse-transcribed 
into cDNA using random primers (Bioneer, Daejeon, Korea) and 
SuperScript III Reverse Transcriptase (Invitogen). Gene expression 
was analyzed using SYBR Green on a StepOne Plus thermocycler 
(Applied Biosystems, Foster City, CA). qRT-PCR was performed 
using SYBR Green qPCR Master (PCR Biosystems, Wayne, PA) 
and primers in Table 1, as previously described [36]. 
Behavior test 
Hindlimb locomotor performance was assessed using the open-
field Basso-Beattie-Bresnahan (BBB) scoring system [32]. A rat 
was placed at the center of a circular open field (diameter: 90 cm, 
wall height: 7 cm) with a non-slip floor for 5 min. Locomotor 
activity of the hindlimbs was monitored 1 week after injury and 
weekly for 9 weeks after transplantation. Each score represents 
a distinct motor functional state from 0 (complete paralysis) to 
21 (normal mobility) based on joint movements, stepping ability, 
coordination, and trunk stability. Examinations were performed 
by three observers who were unaware of the treatment received 
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by each rat. All rats with SCI were block-randomized into four 
experimental groups (Sham, Vehicle, Mock-hNSPCs, and GDNF–
hNSPCs; n=5, 24, 18, and 23, respectively) based on the BBB scores 
recorded at week 1 to ensure deficits were equivalent across the 
experimental groups prior to transplantation.
Hindpaw mechanical allodynia was assessed by measuring the 
withdrawal response to mechanical stimulation with von Frey fila-
ments (Stoelting, Wood Dale, IL) placed on the mid plantar surface 
of the hindpaw. Before testing, rats were housed in the test cage 
above a metal mesh and acclimatized for 30 min. The mechanical 
threshold of a rat was tested prior to surgery and at 14, 28, 42, and 
56 days after transplantation. The 50% withdrawal mechanical 
threshold was measured using Dixon’s up-and-down method [41]. 
A series of von Frey filaments (log unit: 3.61, 3.84, 4.08, 4.31, 4.56, 
4.74, 4.93 and 5.18) were serially applied to the hindpaw with an 
interval of 10 s in six applications, beginning with the 4.31 log unit 
von Frey filament.
Statistical analysis
All statistical analyses were performed using SPSS version 23 
(IBM Corp., Armonk, NY, USA). Two groups were compared by 
the Student’s t-test. Comparisons of BBB score and 50% withdraw-
al threshold among study groups were performed with repeated-
measures analysis of variance (ANOVA). Where significant 
differences were observed, one-way ANOVA followed with a Bon-
ferroni post hoc  analysis was applied for pairwise comparisons 
of groups at each time points. Neurite outgrowth, demyelinated 
volume, g-ratio, tract tracing data, lesion and spared tissue volume, 
the level of Nav expression, and immunodensity of NPY, GFAP, 
Schwann/2E, and GABA among study groups were compared by 
one-way ANOVA, followed by Bonferroni post hoc analysis. Sam-
ple sizes were calculated using power analyses with an α-level of 
0.05 and a power of 0.8. Data represent the means±standard error 
of the mean (SEM). p<0.05 was considered statistically significant. 
RESULTS 
In vitro characterization of adenovirus-infected hNSPCs 
The morphology, survival, and proliferation rate of GDNF-hN-
SPCs, Mock-hNSPCs, and hNSPCs were similar under prolifera-
tion conditions. To determine whether virus infection increased 
release of GDNF protein under differentiation conditions, we 
performed immunocytochemistry with an anti-GDNF antibody 
and quantified the amount of GDNF protein secreted into the me-
dia by performing an ELISA. The concentration of GDNF in CM 
of GDNF-hNSPCs was 13.30±0.28 pg/mL and 22.70±1.12 pg/mL 
after 1 and 3 days, respectively (n=3 per group), while hNSPCs and 
Mock-hNSPCs (2.5×105) did not express or release GDNF (Fig. 1A 
and 1B). Upon culture under differentiation conditions for 7 days, 
the percentages of cells expressing the early neuronal cell marker 
neuronal class III β-tubulin (Tuj1) and the astrocyte marker GFAP 
were higher and lower, respectively, among GDNF-hNSPCs than 
among Mock–hNSPCs (Tuj1, 39.4%±3.7% vs. 25.4%±3.0%, p<0.05; 
GFAP, 71.7%±3.5% vs. 82.4%±1.1%, p<0.05; n=5 per group; Fig. 1C 
and 1D). In addition, while approximately 67% and 7% of Mock-
hNSPC-derived neurons expressed glutamate and GABA, respec-
tively, approximately 35% and 33% of GDNF-hNSPC-derived 
neurons expressed glutamate and GABA, respectively. Some of 
Mock- and GDNF-hNSPCs differentiated into oligodendrocytes 
that expressed the oligodendrocyte progenitor cell (OPC) marker 
O4 (21.8%±6.0% vs. 25.3%±3.0%) and the oligodendrocyte pre-
cursor cell marker PDGFR (19.3%±4.5% vs. 29.5±6.0%), although 
most cells expressed immature cell marker nestin (87.5%±1.6% vs. 
85.0%±2.1%; Fig. 1C and 1D). The sum of the percentages of cells 
expressing each of these markers was higher than 100%, suggest-
ing that some cells expressed multiple markers. Nestin colocalizes 
with β-tubulin III, GFAP, and an oligodendroglial progenitor 
marker [42]. Additionally, GFAP expression does not always indi-
cate acquisition of an astroglial fate in hNSPCs because immature 
hNSPCs are also GFAP+. These findings demonstrate that GDNF-
hNSPCs preferentially differentiate into neurons, although most 
remain immature in vitro. 
We investigated whether factors secreted by GDNF–hNSPCs 
stimulated neurite outgrowth of SH-SY5Y neuroblastoma cells. 
Both GDNF- and Mock-CM significantly enhanced neurite 
length compared with that in the control group (86.1±3.5 µm vs. 
38.3±1.8 µm, p<0.001 and 59.0±2.7 µm vs. 38.3±1.8 µm, p<0.001, 
respectively; Fig. 1E and 1F). In addition, neurite outgrowth was 
enhanced more by GDNF-CM than by Mock-CM (p<0.01; Fig. 
1E and 1F). To confirm that GDNF secreted by GDNF-hNSPCs 
directly affects neurite outgrowth of SH-SY5Y cells, an immu-
nodepletion study was performed. Neurite length of SH-SY5Y 
cells treated with GDNF-CM pre-incubated with an anti-GDNF 
antibody was significantly shorter than that of SH-SY5Y cells 
treated with GDNF-CM pre-incubated with isotype-matched IgG 
(62.4±3.1 µm vs. 81.9±3.4 µm; p<0.05; Fig. 1E and 1F). Therefore, 
GDNF secreted by GDNF-hNSPCs is directly associated with 
neurite outgrowth.
Engraftment, distribution, and differentiation of GDNF-
hNSPCs following transplantation
Nine weeks after implantation of GDNF-hNSPCs into the in-
jured spinal cord of rats, grafted cells showed robust engraftment, 
long-term survival, an extensive distribution throughout the in-
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Fig. 1. In vitro and in vivo characterization of GDNF-hNSPCs. (A) Compared with Mock-hNSPCs (DAPI+, blue), many of GDNF-hNSPCs express 
GDNF (green). (B) An ELISA of GDNF in Mock- and GDNF-CM. (C, D) Representative images of Mock- and GDNF-hNSPCs stained for differentia-
tion markers and quantification of the percentages of cells that expressed these markers. DAPI+ Cells (blue) express nestin (red), GFAP (green), Tuj1 (red), 
PDGFR (green), and O4 (red). (E, F) Representative images of CM-treated SH-SY5Y cells and quantification of average neurite length under different 
experimental conditions. (G) hNuc+ GDNF–hNSPCs (red) implanted into the injured spinal cord show robust engraftment and an extensive distribu-
tion throughout the lesion and adjacent areas. The boxed area is shown at high magnification in the right panel. The asterisk indicates the lesion epicen-
ter and arrows indicate the cell transplantation sites rostral and caudal to the lesion epicenter. (H, I) Representative images of Mock- and GDNF-hN-
SPCs stained for differentiation markers in vivo and quantification of the percentages of cells that expressed these markers. Confocal images show that 
hNSPCs positive for the human cell markers Ku80, STEM101, and STEM121 colocalize with differentiation markers (green). (J) Engrafted STEM121+ 
GDNF-hNSPCs (red) express GDNF (green). Scale bars: 50 µm in A, D; 100 µm in E; 1 mm in G; and 30 µm in I, J. Data represent the means±SEM. 
*p<0.05 vs. Mock-hNSPCs in C, H; *p<0.05 vs. vehicle, ***p<0.001 vs. vehicle, ##p<0.01 vs. Mock-hNSPCs in F.
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jured spinal cord, and integration toward the peri-lesion site (Fig. 
1G). The percentages of cells expressing the early neuronal marker 
Tuj1 and the oligodendroglial progenitor marker Olig2 were 
significantly higher among grafted GDNF-hNSPCs than among 
grafted Mock-hNSPCs (TUJ1, 38.4%±3.0% vs. 21.3%±3.7%, 
p<0.05 and Olig2, 13.5%±1.3% vs. 1.5%±0.3%, p<0.05, respec-
tively; Fig. 1H and 1I). The majority of grafted GDNF- and Mock-
hNSPCs expressed nestin and GFAP (nestin, 70.2%±4.5% vs. 
80.1%±6.0% and GFAP, 71.5%±2.4% vs. 78.5%±3.3%, respectively) 
although the percentages of cells expressing these markers tended 
Fig. 2. Grafted GDNF-hNSPCs enhance neurite outgrowth, axonal extension, and myelination in the injured spinal cord. (A) Multiple NF+ neuronal 
processes (green) extend over engrafted hNuc+ human cells (red). Compared with Mock-hNSPCs, GDNF-hNSPCs significantly enhance neurite ex-
tension and host axonal sprouting. Arrows indicate hNuc+ donor-derived cells (red) and arrowheads indicate NF+ neuronal fibers (green). (B) Under 
high magnification, many NF+ neuronal processes (red) are co-labeled with an anti-MBP antibody (green). Arrowheads indicate co-labeled myelinated 
neuronal fibers (yellow or orange). (C) The intensity of MBP staining in engrafted and adjacent areas is markedly higher in the GDNF-hNSPC-treated 
group than in the Mock-hNSPC-treated group. Arrows indicate hNuc+ donor-derived cells (red) and arrowheads indicate MBP+ myelinated neuronal 
fibers (green). (D) Representative images of LFB staining (blue) in the lesion and adjacent areas of the spinal cord. Dashed lines indicate demyelinated 
areas. (E) Quantification of the demyelinated volume in the different experimental groups. (F, G) Representative electron microscopic images of axially 
sectioned spinal cords (T8~T10) and quantification of G-ratio. (H, I) Representative images of Schwann/2E immunostaining (green) in the injured spinal 
cords and quantification of immunostaining density in the different experimental groups. Scale bars: 1 mm in A, C, D; 100 µm in B; 1 µm in F, and 500 
µm in H. Data represent the means±SEM. *p<0.05 vs. vehicle, #p<0.01 vs. Mock-hNSPCs.
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to be lower among GDNF-hNSPCs than among Mock-hNSPCs. 
Low percentages of grafted GDNF- and Mock-hNSPCs expressed 
the astrocyte marker S100β (3.5%±0.9% vs. 5.1%±0.2%, respec-
tively; Fig. 1H and 1I). Grafted GDNF-hNSPCs also expressed 
GDNF in the injured spinal cord (Fig. 1J). These data demonstrate 
that GDNF-hNSPCs implanted into the injured spinal cord show 
robust engraftment, long-term survival, an extensive distribution, 
and differentiate into all three CNS neural cell types (preferentially 
neurons and oligodendrocytes), although most remain immature. 
Implantation of GDNF-hNSPCs enhances neurite  
outgrowth, axonal extension and myelination in the  
injured spinal cord
When spinal cords were analyzed at 9 weeks post-transplanta-
tion, many hNuc+ GDNF- and Mock-hNSPCs had survived and 
migrated extensively to sites rostral and caudal to the lesion epi-
center, including spared tissue surrounding the lesion. In addition, 
multiple neuronal processes expressing NF extended over engraft-
ed human cells (Fig. 2A). Compared with grafted Mock-hNSPCs, 
grafted GDNF-hNSPCs markedly promoted neurite extension 
and induced host axonal sprouting (Fig. 2A). These findings sug-
gest that GDNF is one of the most important factors secreted by 
implanted GDNF-hNSPCs to promote neurite outgrowth and 
axonal extension in SCI. 
High magnification imaging revealed that many NF+ neuronal 
processes were co-labeled with an antibody to the mature oligo-
dendrocyte marker myelin basic protein (MBP) (Fig. 2B). To in-
vestigate the effect of GDNF-hNSPCs on axonal myelination after 
SCI, histological analysis was performed with an anti-MBP anti-
body and LFB at 9 weeks post-implantation. The intensity of MBP 
staining in engrafted sites and adjacent areas was markedly higher 
in the GDNF-hNSPC-treated group than in the Mock-hNSPC-
treated group (Fig. 2C). Staining with LFB and CV was performed 
to label myelinated regions in parasagittal sections of the spinal 
cord. The blue area indicated myelinated axons, whereas the violet 
area indicated demyelination of axons. The demyelinated volume 
percentage (relative to the total tissue volume) in injured and 
adjacent areas was significantly lower in the Mock-hNSPC- and 
GDNF-hNSPC-treated groups than in the vehicle-treated group 
(vehicle, 29.4%±1.5% vs. Mock-hNSPCs, 21.3%±1.9%, p<0.05 and 
vehicle vs. GDNF-hNSPCs, 14.0%±1.4%, p<0.05). Furthermore, 
the demyelinated volume percentage was significantly lower in the 
GDNF-hNSPC-treated group than in the Mock-hNSPC-treated 
group (p<0.05; Fig. 2D and 2E). To investigate the arrangement of 
oligodendrocyte-remyelinated axons, the G-ratio was measured 
using electron microscopy images. The lower the G-ratio, the 
greater is the extent of remyelination. Conversely, a higher G-ratio 
indicates thinner myelin sheaths and incomplete remyelination. 
The G-ratio was significantly lower in the Mock-hNSPC- and 
GDNF-hNSPC-treated groups than in the vehicle-treated group 
(0.72±0.01 vs. 0.77±0.01, p<0.05 and 0.67±0.01 vs. 0.77±0.01, 
p<0.05, respectively). In addition, the G-ratio was significantly 
lower in the GDNF-hNSPC-treated group than in the Mock-
hNSPC-treated group (p<0.05; Fig. 2F and 2G). These findings in-
dicate that grafted GDNF-hNSPCs enhance host axonal regenera-
tion and myelination in the injured spinal cord. Moreover, myelin 
sheaths of regenerated axonal fibers were thicker in the GDNF-
hNSPC-treated group than in the vehicle- and Mock-hNSPC-
treated groups at the ultrastructural level.
To assess SCs after SCI, we measured the immunostaining 
density of the SC marker Schwann/2E in the injured spinal cord. 
The immunostaining density were normalized against that in the 
vehicle-treated group. The normalized Schwann/2E immunos-
taining density was significantly higher in the GDNF-hNSPC- and 
Mock-hNSPC-treated groups than in the vehicle-treated group 
(165.4%±6.8% and 131.7%±4.0%, p<0.05, respectively). Moreover, 
Fig. 2. Continued.
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it was significantly higher in the GDNF-hNSPC-treated group 
than in the Mock-hNSPC-treated group (p<0.05; Fig. 2H and 2I). 
Thus, grafted GDNF-hNSPCs substantially facilitate infiltration 
of SCs into the injured spinal cord and this contributes to myelin 
repair.
Implantation of GDNF-hNSPCs protects some injured cor-
ticospinal fibers, promotes the formation of detour circuits, 
and reduces lesion volume and glia scar formation
To examine whether GDNF-hNSPCs implanted into the in-
jured spinal cord protect the dCST, BDA was injected into the 
sensorimotor cortex at 6 weeks post-transplantation. Texas Red-
labeled dorsal corticospinal axonal fibers in tissue adjacent to the 
Fig. 3. Grafted GDNF-hNSPCs protect the dCST, promote the formation of detour circuits, and reduce lesion volume and glia scar formation. (A) 
Representative images of BDA-labeled dCST fibers (red) at 6 mm rostral to the lesion epicenter in the different experimental groups. The boxed areas in 
the left panels are shown at high magnification in the right panels. (B) Quantification of the number of dCST fibers up to 6 mm rostral and caudal to the 
lesion epicenter. (C) Representative images of dCST collaterals (black, left panel) and FG-labeled PSNs (white, right panel) in the cervical enlargement of 
the spinal cord in the different experimental groups. The white dashed lines in the right panel indicate the margins between gray and white matter of the 
spinal cord. (D) Quantification of dCST collaterals and FG-labeled PSNs in the cervical enlargement. (E) Representative images of the contacts between 
dCST collaterals (black) and PSNs (brown) in the cervical enlargement. Arrowheads show closely located collateral fibers and PSNs. (F) Quantification 
of the number of contacts between dCST collaterals and PSNs. (G) Representative images of GFAP immunostaining in the lesion and adjacent areas 
of the spinal cord in the different experimental groups. Dashed lines indicate GFAP-negative areas. (H) Quantification of lesion volume, spared tissue 
volume, and glial scars. Scale bars: 100 µm in A, C; 40 µm in E; and 1 mm in G. Data represent the means±SEM. *p<0.05 vs. vehicle, ***p<0.001 vs. vehicle, 
#p<0.01 vs. Mock-hNSPCs.
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lesion epicenter were detected 3 weeks later. The density of BDA-
labeled fibers at 6 mm rostral to the lesion epicenter was markedly 
higher in the GDNF-hNSPC-treated group than in the vehicle- 
and Mock-hNSPC-treated groups (Fig. 3A). The number of dCST 
fibers at 4, 5, and 6 mm rostral to the lesion epicenter was higher in 
the GDNF-hNSPC-treated group than in the Mock-hNSPC- and 
vehicle-treated groups (p<0.05; Fig. 3B). However, BDA-labeled 
dCST fibers were not detected caudal to the injury epicenter in 
any group. 
To examine whether GDNF-hNSPCs implanted into the injured 
spinal cord promote the formation of detour circuits in the same 
group of rats, the retrograde tracer FG was injected into the spinal 
cord at the L2 level at 8 weeks after injection of GDNF-hNSPCs, 
Mock-hNSPCs, or vehicle. At 9 weeks post-injection, the numbers 
of collaterals sprouting from the main dCST, PSNs, and contacts 
between collaterals and PSNs were counted in the cervical enlarge-
ment of the spinal cord. When the number of collaterals from the 
dCST was divided by the number of main dCSTs in the same sec-
tions, the percentage of collaterals was significantly higher in the 
GDNF-hNSPC-treated group than in the vehicle-treated group 
(2.1±0.4% vs. 0.5±0.2%, p<0.05). This value tended to be higher in 
the Mock-hNSPC-treated group than in the vehicle-treated group; 
however, this difference was not significant (1.3±0.4% vs. vehicle; 
Fig. 3C and 3D). The average number of FG-labeled PSNs was 
significantly higher in the GDNF-hNSPC-treated group than in 
the vehicle-treated group (4.9±1.0 vs. 0.7±0.4, p<0.05). This value 
tended to be higher in the Mock-hNSPC-treated group than in the 
vehicle-treated group; however, this difference was not significant 
(1.0±0.3 vs. vehicle; Fig. 3C and 3D). Contacts between dCST col-
laterals and PSNs were observed in the GDNF-hNSPC-treated 
group, but not in the Mock-hNSPC- and vehicle-treated groups 
(Fig. 3E and 3F). These results suggest that implantation of GDNF-
hNSPCs protects some injured corticospinal fibers and promotes 
the formation of detour circuits in the injured spinal cord. 
To examine the neuroprotective effects of GDNF-hNSPC 
implantation on the injured spinal cord, we assessed the lesion 
volume, spared tissue volume, and glia scar formation by perform-
ing immunostaining for GFAP at 9 weeks post-transplantation. 
Lesion volume was significantly smaller in the Mock-hNSPC- and 
GDNF-hNSPC-treated groups than in the vehicle-treated group 
(3.1±0.3 mm3 vs. 4.3±0.2 mm3, p<0.05 and 1.6±0.3 mm3 vs. 4.3±0.2 
mm3, p<0.001, respectively). Moreover, lesion volume was signifi-
cantly smaller in the GDNF-hNSPC-treated group than in the 
Mock-hNSPC-treated group (p<0.05; Fig. 3G and 3H). Spared tis-
sue volume was significantly larger in the GDNF-hNSPC-treated 
group than in the vehicle-treated group (13.6±1.0 mm3 vs. 9.0±0.7 
mm3, p<0.05), but did not differ between the vehicle- and Mock-
hNSPC-treated groups (vehicle vs. 10.9±1.0 mm3; Fig. 3G and 3H). 
In addition, the normalized GFAP immunostaining density was 
significantly lower in the GDNF-hNSPC- and Mock-hNSPC-
treated groups than in the vehicle-treated group (64.8%±3.1%, 
p<0.001 and 83.2%±1.0%, p<0.05, respectively) and was signifi-
cantly lower in the GDNF-hNSPC-treated group than in the 
Mock-hNSPC-treated group (p<0.05; Fig. 3G and 3H). These 
results suggest that grafted GDNF-hNSPCs significantly reduce 
tissue damage and glia scar formation in the lesion epicenter and 
adjacent areas of the injured spinal cord.
Implantation of GDNF-hNSPCs facilitates motosensory re-
covery 
We evaluated the capacity of implanted GDNF-hNSPCs to 
improve hindlimb locomotor function in rats with SCI using the 
open-field BBB scoring system. BBB scores were around 21 in all 
sham groups. Prior to transplantation, BBB scores did not differ 
among the three groups. BBB scores across different time points 
before and after cell transplantation were significantly different 
Fig. 3. Continued.
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among experimental groups (p=0.000). GDNF-hNSPCs induced 
significant functional recovery at 1, 2, 3, 4, 5, 6, 7, 8, and 9 weeks 
post-transplantation compared with the vehicle control (4.2±0.3 
vs. 2.9±0.3; 5.4±0.4 vs. 3.8±0.4; 6.4±0.5 vs. 3.9±0.4; 7.2±0.5 vs. 
4.5±0.4; 7.4±0.6 vs. 4.2±0.4; 7.4±0.6 vs. 4.4±0.5; 7.7±0.6 vs. 4.5±0.5; 
7.8±0.6 vs. 4.6±0.4; and 7.8±0.6 vs. 4.3±0.5, respectively; Fig. 4A). 
Fig. 4. Transplantation of GDNF-hNSPCs promotes motosensory recovery, reduces expression of voltage-gated sodium channels and NPY, and in-
creases expression of GABA. (A) The BBB open-field walking scores before transplantation and at various time points post-transplantation. (B) Von 
Frey tests for mechanical allodynia in lesioned hindlimbs of rats with SCI before transplantation and at various time points post-transplantation. (C) 
qRT-PCR analysis of Nav1.3 and Nav1.9 expression in the T8~T10 segment of the spinal cord. (D, E) Representative images and quantification of NPY 
expression in lamina I of the dorsal horn in the T8 segment of the spinal cord. (F, G) Representative images and quantification of GABA expression in the 
T8~T10 segment of the spinal cord. (H) Many engrafted hNuc
+ GDNF-hNSPCs (red, arrowheads) express GABA (green, arrowheads) adjacent endog-
enous GABA+ cells (green, arrows). Scale bars: 200 µm in D; 500 µm in F; and 50 µm in H. Data represent the means±SEM. *p<0.05 vs. vehicle, **p<0.01 
vs. vehicle, ***p<0.001 vs. vehicle, #p<0.05 vs. Mock-hNSPCs, ##p<0.01 vs. Mock-hNSPCs in A, B. *p<0.05 vs. vehicle, #p<0.05 vs. Mock-hNSPCs in C, E, 
and G.
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BBB scores were significantly higher in the GDNF-hNSPC-treated 
group than in the Mock-hNSPC-treated group at 1, 3, 4, 5, 7, 8, 
and 9 weeks post-transplantation (4.2±0.3 vs. 3.0±0.4; 6.4±0.5 vs. 
4.5±0.5; 7.2±0.5 vs. 5.0±0.5; 7.4±0.6 vs. 5.4±0.6; 7.7±0.6 vs. 5.8±0.6; 
7.8± 0.6 vs. 5.7±0.6; and 7.8±0.6 vs. 5.8±0.5, respectively; Fig. 4A). 
BBB scores tended to be higher in the Mock-hNSPC-treated group 
than in the vehicle-treated group; however, this difference was not 
statistically significant. These data demonstrate that implantation 
of GDNF-hNSPCs improves hindlimb locomotor performance of 
rats with SCI without causing abnormal neurological behaviors. 
We also assessed the effects of GDNF-hNSPC implantation on 
development of neuropathic pain after SCI by evaluating mechan-
ical allodynia via the von Frey test. The mechanical withdrawal 
threshold across different time points before and after cell trans-
plantation were significantly different among experimental groups 
(p=0.000). The mechanical withdrawal threshold in the vehicle-
treated group was much lower at 2, 4, 6, and 8 weeks post-injection 
than prior to injury (4.4±0.9, 2.6±0.4, 2.6±0.3, and 1.9±0.4, respec-
tively; Fig. 4B). The mechanical withdrawal threshold was signifi-
cantly higher in the Mock-hNSPC-treated group than in the vehi-
cle-treated group at 4, 6, and 8 weeks post-transplantation (5.7±1.2 
vs. vehicle; 6.8±1.4 vs. vehicle; and 6.7±1.1 vs. vehicle, respectively; 
Fig. 4B). The mechanical withdrawal threshold was significantly 
higher in the GDNF-hNSPC-treated group than in the vehicle-
treated group at 2, 4, 6, and 8 weeks post-transplantation (9.2±1.0 
vs. vehicle,; 10.1±0.8 vs. vehicle; 10.9±0.9 vs. vehicle; and 10.3±1.1 
vs. vehicle, respectively). Furthermore, the mechanical withdrawal 
threshold was significantly higher in the GDNF-hNSPC-treated 
group than in the Mock-hNSPC-treated group at 4, 6, and 8 weeks 
post-transplantation (Fig. 4B). In the sham group, the mechani-
cal withdrawal threshold was 15±0.2. Hence, transplantation of 
GDNF-hNSPCs efficiently attenuates mechanical allodynia after 
SCI.
Implantation of GDNF-hNSPCs reverses the upregulation 
of voltage-gated sodium channels and NPY in the dorsal 
horn and increase GABA expression after SCI 
To investigate the effect of GDNF-hNSPC implantation on ex-
pression of voltage-gate sodium channels (Nav) linked with neu-
ropathic pain in SCI, we analyzed Nav1.3 and Nav1.9 expression 
in the T8~T10 segment of the spinal cord at 9 weeks post-transplan-
tation by performing qRT-PCR. Expression of Nav1.3 (1.61±0.09-
fold, p<0.05) and Nav1.7 (2.25±0.29-fold, p<0.05) was higher in 
the vehicle-treated group than in the sham-operated control. Ex-
pression of Nav1.3 (1.45±0.07-fold) and Nav1.7 (1.86±0.20-fold) 
tended to be lower in the Mock-hNSPC-treated group than in the 
vehicle-treated group; however, these differences were not signifi-
cant. However, expression of Nav1.3 (0.95±0.19-fold, p<0.05) and 
Nav1.7 (1.15±0.15-fold, p<0.05) in the GDNF-hNSPC-treated 
group was comparable with that in the sham-operated control 
and was significantly lower than that in the vehicle-treated group 
(Fig. 4C). In addition, expression of Nav1.3 was significantly lower 
in the GDNF-hNSPC-treated group than in the Mock-hNSPC-
treated group. 
The normalized NPY immunostaining density at lamina I of the 
dorsal horn in the T8 segment of the spinal cord was significantly 
higher at 9 weeks after vehicle injection (129.85%±4.89%, p<0.05) 
than in the sham-operated control. However, the normalized NPY 
immunostaining density in the GDNF-hNSPC-treated group 
(106.28%±3.14%, p<0.05) was similar to that in the sham-operated 
control and was significantly lower than that in the vehicle-
treated group. The normalized NPY immunostaining density 
tended to be lower in the Mock-hNSPC-treated group than in the 
vehicle-treated group; however, this difference was not significant 
(115.69%±1.37%; Fig. 4D and 4E). 
The normalized GABA immunostaining density in the T8~T10 
segment of the spinal cord at 9 weeks post-transplantation 
was significantly higher in the GDNF-hNSPC-treated group 
(198.36±24.81%) than in the vehicle-treated group and tended 
to be higher in the Mock-hNSPC-treated group than in the 
vehicle-treated group; however, this difference was not significant 
(131.04±9.48%; Fig. 4F and 4G). Histochemical analysis confirmed 
that many implanted GDNF-hNSPCs expressed GABA and thus 
gave rise to GABAergic cells in the injured spinal cord (Fig. 4H). 
These results suggest that reversion of Nav and NPY upregulation 
and increased GABA expression upon implantation of GDNF-
hNSPCs alleviates mechanical allodynia after SCI.
DISCUSSION
SCI is a devastating, life-changing disorder with many serious 
consequences and no known effective treatment. Cell transplanta-
tion has emerged as a promising therapeutic method to enhance 
repair following SCI. Various types of cells, including SCs, oligo-
dendrocyte precursor cells, NSPCs, MSCs, and olfactory ensheath-
ing cells, have been evaluated in terms of their capacity to regener-
ate the injured spinal cord upon transplantation [43]. Although 
cell transplantation has been intensely studied, it remains unclear 
how implanted cells yield therapeutic effects in SCI. We previously 
reported that human fetal brain-derived primary NSPCs implant-
ed into the injured spinal cord of adult rats exhibit robust engraft-
ment, extensive migration, long-term survival, and differentiation 
into neuronal and glial cells, although most remain immature, re-
sulting in modest improvement of motosensory function [18, 44]. 
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Following implantation, hNSPCs are suggested to have functional 
benefits for SCI via a variety of mechanisms, including neuropro-
tection, neural plasticity, immunomodulation, angiogenesis, neu-
rite outgrowth, axonal extension, and cellular replacement [18, 44]. 
Based on these preliminary data, several early-phase clinical trials 
were performed. These demonstrated that transplantation of hu-
man fetal brain- or spinal cord-derived NSPCs is generally feasible 
and safe, and yields minimal or modest neurological improve-
ment; however, the long-term efficacy and safety remain unproven 
[18-20]. The patterns of cellular responses to SCI are extremely 
heterogeneous and complex; therefore, simply delivering specific 
neural cell types into the injured spinal cord via cell or stem cell 
therapy is ineffective [44]. Thus, the therapeutic efficiency of hN-
SPCs for SCI is insufficient and there is no cure for this condition.
One possible treatment strategy for SCI is to prevent neurode-
generation and stimulate regeneration using GDNF. GDNF has 
extensive effects on repair after SCI and these have been broadly 
examined. To improve the therapeutic efficiency of GDNF, future 
research should focus on enhanced delivery methods using bio-
materials, nanoparticles, viral vectors, or genetically modified cells 
to secrete both GDNF and other trophic factors over time [29, 30, 
44]. Previous research indicated that direct in vivo GDNF gene 
therapy using viral vectors or plasmid DNA protects motor neu-
rons and promotes functional recovery after SCI [45]. Adenovirus- 
or herpes simplex virus-mediated GDNF gene therapy reduces 
motor neuron injury, preserves neuronal fibers, and improves 
locomotor function in rats with SCI [46-49]. However, in vivo 
gene therapy using viral vectors is associated with several compli-
cations, including non-specific targeting and gene expression, gene 
silencing, and an immune response to the vector [50]. 
Ex vivo gene therapy allows the genetically engineered cell prod-
uct to be characterized in vitro prior to administration and does 
not involve direct exposure of the patient to the viral vector. In 
addition, grafted genetically modified cells not only replace the 
neural cell types lost to injury and support diseased neurons and/
or dysfunctional glia, but also produce additional endogenous tro-
phic and immunomodulatory molecules that augment their thera-
peutic potential. Various cell types have been used in combined 
cell and gene therapeutic approaches to provide GDNF to the 
injured spinal cord [29, 30]. GDNF-overexpressing SCs implanted 
into the injured spinal cord modulate astrocytic glial scars, pro-
mote propriospinal axonal regeneration and synapse formation, 
and improve functional recovery [51]. Implantation of hydrogel 
scaffolds containing GDNF-overexpressing SCs into the transect-
ed spinal cord also promotes axonal growth and axon myelination 
[52]. Grafted genetically modified GDNF-secreting MSCs or um-
bilical cord blood-derived mononuclear cells induce functional 
recovery and tissue sparing, and increase myelination after SCI [45, 
53]. These studies suggest that ex vivo GDNF gene therapy with 
multiple cell types has beneficial effects for spinal cord repair. This 
may be because the complicated and dynamic milieu resulting 
from SCI seems to require combinational treatment approaches. 
However, while immortalized mouse NSCs constitutively secrete 
GDNF together with other neurotrophic factors and promote 
axonal growth after SCI, implantation of mouse NSCs genetically 
engineered to overexpress GDNF into the injured spinal cord does 
not improve locomotor function and significant forelimb thermal 
and mechanical allodynia because these cells exclusively undergo 
astrocytic differentiation [9, 54]. 
Human fetal cortex-derived primary NSPCs genetically modi-
fied to stably express GDNF using a lentivirus survive, migrate, 
secrete GDNF, and protect degenerating neurons [55, 56]. These 
cells are safe and non-tumorigenic, and are currently being used 
in a phase 1/2a clinical trial incorporating cell and gene therapy 
to protect motor neurons in patients with amyotrophic lateral 
sclerosis [57]. Therefore, in this study, we evaluated the regenera-
tive ability of human fetal brain-derived NSPCs engineered to 
secrete GDNF via infection of an adenovirus in rats with SCI and 
compared their therapeutic efficiency with that of Mock-hNSPCs 
for a future clinical trial. Ex vivo transduction of hNSPCs with a 
GDNF-encoding adenoviral vector leads to effective expression of 
GDNF. In addition, GDNF-hNSPCs might secrete multiple other 
active factors that enhance neuronal survival and neuroplasticity, 
reduce secondary damage, and stimulate the endogenous repair 
system via inducing favorable changes in the environmental 
milieu of the damaged spinal cord [31, 44]. In the present study, 
although GDNF-hNSPCs were implanted into the injured spinal 
cord at 7 days after SCI during the subacute stage, they showed 
robust engraftment, long-term survival, an extensive distribution, 
and increased differentiation into neurons and oligodendroglial 
cells in the lesion and adjacent sites. Therefore, grafted cell-derived 
GDNF and other therapeutic molecules diffuse beyond the en-
graftment sites over a long period, which may contribute to exten-
sive neuroprotection, decreased lesion volume, promotion of neu-
rite outgrowth and axonal extension, increased SC migration and 
myelination, modulation of astrocytic glial scars, and improved 
motosensory function post-SCI.
Compared with grafted Mock-hNSPCs, grafted GDNF-hNSPCs 
showed increased differentiation into neurons and oligodendro-
cytes, although most remained immature, and these cells might be 
able to reconstitute the injured spinal cord. However, further stud-
ies are needed to electrophysiologically confirm the functional 
neural connections and efficient axonal connectivity between host 
and donor-derived neurons. 
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SCI induces neuronal death at the injury site and extensive axo-
nal dieback of the dCST, which is pivotal for voluntary movement 
[58]. Neuroprotection of damaged axons and increased axonal 
plasticity are important for locomotor recovery. hNSPCs produce 
various neurotrophic factors that support neuroprotection and 
neurite outgrowth [31]. In addition, GDNF promotes axonal 
plasticity in CSTs and newly formed PSNs after SCI [59, 60]. After 
SCI, transected mid-thoracic CST axons sprouted into the cervical 
gray matter where they contact descending ‘long’ and ‘short’ PSNs. 
Long PSNs originate in the cervical enlargement (C3~C5), travel in 
the ventral and lateral funiculi, and terminate in the ventral horn 
of the lumbosacral enlargement bridging spinal levels above and 
below the lesion. In contrast, short PSNs connect the upper (C3~C4) 
and lower (C6~T1) cervical cord, not bridging spinal levels above 
and below the lesion. Transected CST axons sprout into short 
and long PSNs in the cervical enlargement equally, but sprouts 
that contacted long PSNs are maintained, thereby creating a new 
intraspinal circuit (detour circuit) [40]. In this study, transplanted 
GDNF-hNSPCs induced host axonal regrowth, protected the 
dCST, and increased the number of PSNs and contacts between 
dCST collaterals and PSNs in the cervical enlargement promoting 
the formation of detour circuits in the injured spinal cord. 
In terms of motor function recovery after SCI, a previous study 
reported that grafted GDNF-secreting olfactory ensheathing cells 
and GDNF-secreting SCs increased the BBB score by almost 8 and 
about 5 compared with controls, respectively [30]. In this study, the 
BBB score was approximately 3.5 higher in the group transplanted 
with GDNF-hNSPCs during the subacute stage after severe contu-
sive SCI than in the control group at 9 weeks post-transplantation. 
However, it is difficult to directly compare the improvements of 
BBB scores between studies because the type of SCI (contusion, 
hemisection, and complete transection), level of injury, concentra-
tion of secreted GDNF, GDNF delivery method, and timing of 
transplantation after SCI differ. 
In animal models, GDNF exerts potent analgesic effects on neu-
ropathic pain, although the underlying mechanisms have not been 
completely elucidated [61]. GDNF reverses nerve injury-induced 
changes, including expression of the P2X3 purinoreceptor, sodium 
channels, neuropeptides, and regulator of G-protein signaling pro-
tein 4, as well as IB4 binding, in dorsal root ganglion neurons [61]. 
However, effective GDNF delivery methods to relieve neuropathic 
pain are still under investigation. In addition, GDNF-hNSPCs 
were more differentiated into GABA+ neurons than Mock-
hNSPCs. Thus, the increased supply of donor-derived GABAergic 
neurons may be able to restore the inhibitory function to the spinal 
cord dorsal horn to decrease the hyperexcitability that develops 
in dorsal horn projection neurons [62-65]. The increased GABA 
production is a potential mechanism of behavioral improvement 
in the allodynic rat after SCI. Furthermore, GABA as well as other 
trophic factors including GDNF secreted by transplanted cells 
would protect endogenous spinal cord inhibitory interneurons 
after SCI. Thus, not only Mock-hNSPCs but also GDNF-hNSPCs 
implanted into SCI would attenuate neuropathic pain. Taken to-
gether, grafted GDNF-hNSPCs reversed the upregulation of Nav 
and NPY, increased GABA expression, and a rare differentiation of 
donor-derived cells into astrocytes, which contributed to marked 
alleviation of mechanical allodynia after SCI. 
Demyelination is a major hurdle for recovery after SCI. Although 
resident OPCs can replace damaged oligodendrocytes, the inhibi-
tory milieu of the injured spinal cord prevents mature myelination 
[66]. Transplantation of OPCs or SCs is effective for SCI recovery 
[67, 68]. However, OPCs and SCs are difficult to isolate and this 
limits their use. In this study, grafted GDNF-hNSPCs showed 
increased differentiation into oligodendrocytes and enhanced 
migration of SCs toward the injured spinal cord. SCs migrate to 
lesion sites in the spinal cord, participate in remyelination in these 
areas, and support axonal growth [45]. GDNF stimulates migra-
tion of SCs and enhances myelination through the NCAM signal-
ing pathways that regulate myelin formation [69]. Thus, the com-
binational approach using hNSPCs and GDNF induced robust 
remyelination in damaged areas by host SCs and donor-derived 
oligodendrocytes after SCI. 
In summary, transplantation of GDNF-hNSPCs is a promis-
ing combinational treatment approach to enhance repair of the 
injured spinal cord. The GDNF gene was efficiently transduced 
using an adenoviral vector, and GDNF-hNSPCs expressed GDNF 
for a long duration both in vitro and in vivo. GDNF-hNSPCs im-
planted into the injured spinal cord showed robust engraftment, 
long-term survival, an extensive distribution, and increased differ-
entiation into neurons and oligodendrocytes in the lesion and ad-
jacent areas. This resulted in extensive neuroprotection, decreased 
lesion volume, promotion of neurite outgrowth and axonal ex-
tension, increased SC migration and myelination, modulation of 
astrocytic glial scars, and improved functional recovery post-SCI. 
These findings support the investigation of GDNF-hNSPCs in a 
clinical trial for SCI.
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